← Back to Search

Arm A: CxBladder followed by cystoscopy for Bladder Cancer

N/A
Recruiting
Led By Mark D. Tyson, M.D., M.P.H.
Research Sponsored by Mayo Clinic
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 6 months
Awards & highlights

Study Summary

The purpose of this study is to evaluate patient-reported preference for urine based molecular testing (CxBladder Monitor) compared to cystoscopy for patients on surveillance for Nonmuscle Invasive Bladder Cancer (NMIBC). Urine based molecular testing involves noninvasive testing of a urine sample for biomarkers associated with disease recurrence. Cystoscopy is an examination of the bladder and urethra using a thin tube like instrument that is inserted into the urethra.

Eligible Conditions
  • Bladder Cancer

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 6 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 6 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Preference for CxBladder Monitor compared to cystoscopy
Secondary outcome measures
Change in symptoms and function - EORTC NMIBC-24
Error rate identifying recurrent nonmuscle invasive bladder cancer (NMIBC)
Fear of Cancer Recurrence Inventory- Short Form (FCRI-SF)
+2 more

Trial Design

2Treatment groups
Experimental Treatment
Group I: Arm B: cystoscopy followed by CxBladderExperimental Treatment2 Interventions
Arm B will undergo cystoscopy 3 months after randomization followed by testing with CxBladder 3 months thereafter.
Group II: Arm A: CxBladder followed by cystoscopyExperimental Treatment2 Interventions
Arm A will undergo testing with CxBladder 3 months after randomization followed by a cystoscopy 3 months thereafter
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Cystoscopy
2016
Completed Phase 4
~810

Find a Location

Who is running the clinical trial?

Mayo ClinicLead Sponsor
3,206 Previous Clinical Trials
3,766,976 Total Patients Enrolled
Mark D. Tyson, M.D., M.P.H.Principal InvestigatorMayo Clinic
1 Previous Clinical Trials
704 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
Urine-based Molecular Testing vs Cystoscopy for Surveillance of Nonmuscle Invasive Bladder Cancer (NMIBC)
Mark D. Tyson II, M.D., M.P.H. 2023. "Urine-based Molecular Testing vs Cystoscopy for Surveillance of Nonmuscle Invasive Bladder Cancer (NMIBC)". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT06126796.
All > Phoenix > Paid Studies Minneapolis
~58 spots leftby Nov 2024
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top